Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
XTL Biopharmaceuticals Ltd. (XTLB) had Return on Tangible Equity of 298.82% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-6.97M |
|
-- |
|
-- |
|
$1.69M |
|
$-1.69M |
|
$0.93M |
|
$-0.76M |
|
$-0.76M |
|
$-0.76M |
|
$-0.76M |
|
$-6.97M |
|
$-0.76M |
|
$-1.69M |
|
$-1.69M |
|
8.96M |
|
8.96M |
|
$-0.80 |
|
$-0.80 |
|
| Balance Sheet Financials | |
$0.17M |
|
-- |
|
-- |
|
$0.17M |
|
$0.42M |
|
-- |
|
-- |
|
$0.42M |
|
$-0.25M |
|
$-0.25M |
|
$-0.25M |
|
9.46M |
|
| Cash Flow Statement Financials | |
$-1.02M |
|
$0.52M |
|
$0.21M |
|
$0.37M |
|
$0.08M |
|
$-0.29M |
|
$0.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.40 |
|
-- |
|
-- |
|
-- |
|
-1.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.02M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
298.82% |
|
|
Return on Tangible Equity |
298.82% |
-457.23% |
|
298.82% |
|
$-0.03 |
|
$-0.11 |
|
$-0.11 |
|